NanoHybrids Inc. Launches Its First Product Line of Imaging Contrast Agents

NanoHybrids develops nano-sized contrast agents that can enhance biomedical imaging techniques by interacting specifically with diseased cells and allowing for real time imaging of functional biology. These products can potentially be employed in a wide variety of applications including optical biomedical imaging, microscopy, molecular diagnostics and theranostic approaches.

Austin, TX, March 07, 2014 --(PR.com)-- NanoHybrids Corporation, a provider of nanotechnology-based contrast agents announced the launch of its new website and premium product line of gold nanoparticles specially designed to improve imaging results. The company’s initial technology platform was developed in collaboration with researchers from the Biomedical Engineering Department at The University of Texas at Austin and M.D. Anderson Cancer Center.

NanoHybrids’ offerings include an exclusive line of silica-coated gold nanorods that are quickly gaining popularity as contrast agents in photoacoustic (optoacoustic) imaging. As opposed to current preclinical imaging contrast agents on the market, NanoHybrids’ silica-coated nanorods resist melting and shape distortion even when subjected to extreme heat via focused laser beams. In addition to providing this enhanced thermodynamic stability, the silica-coating also facilitates better heat transfer to the surrounding fluid, thus dramatically increasing signal strength. Overall, these benefits make the company’s silica-coated gold nanorods an excellent contrast agent for not only in vitro and in vivo photoacoustic imaging but also many other applications involving continuous or pulsed lasers.

The founders at NanoHybrids have decades of experience in biomedical imaging and have been pioneering the development of contrast agents alongside custom designed imaging systems.

About NanoHybrids Inc.: NanoHybrids is an Austin-based company focused on commercializing nanotechnology solutions that can enhance the non-invasive detection and molecular profiling of cancer, atherosclerosis and other diseases. The company’s current product line comprises of nano-sized agents that enhance contrast in pre-clinical biomedical imaging techniques by interacting specifically with diseased cells and allowing for selective real-time imaging of functional biology.

Website: www.nanohybrids.net
Product Applications: http://nanohybrids.net/pages/applications
Products: http://nanohybrids.net/collections/all-products
Contact information: info at nanohybrids.net
Contact
NanoHybrids
Nishi Viswanathan
512-270-8469
www.NanoHybrids.net
ContactContact
Categories